Actively Recruiting
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Led by Bai-Rong Xia · Updated on 2025-08-15
40
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enhance resistance to PD - 1 the activity of the inhibitor, to improve the treatment of mice on the immune response. Non-selective β-blockers can also improve the efficacy of melanoma immunotherapy. Retrospective studies have shown that incidental use of β-blockers in combination with antiangiogenic agents, chemotherapy, and immune therapy can prolong DFS, PFS, and OS in cancer patients. A large, multicenter retrospective study found that ovarian cancer patients who took nonselective β-blockers for hypertension had better survival than those who did not. In conclusion, this study aims to explore new auxiliary chemotherapy combined propranolol treatment of high efficacy and safety of ovarian cancer, provide more evidence-based basis for clinic.
CONDITIONS
Official Title
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 to 75 years
- Histologically confirmed high-grade serous ovarian cancer at FIGO stage III or IV, including inoperable cases
- Measurable lesions according to RECIST 1.1 criteria
- Agreed to provide formalin-fixed or fresh biopsy tumor tissue for marker detection
- ECOG performance status score of 0 to 1
- Expected survival time of at least 6 months
- Adequate organ function with specific laboratory values: hemoglobin ≥90 g/L, neutrophils ≥1.5 x 10^9/L or white blood cells ≥3 x 10^9/L, platelets ≥90 x 10^9/L, AST and ALT ≤2.5 times upper limit of normal, total bilirubin ≤1.5 times upper limit of normal, serum creatinine ≤1.0 times upper limit of normal
- Negative serum or urine HCG test within 7 days before treatment for women of childbearing potential; postmenopausal women must have at least 12 months of amenorrhea
- Women of childbearing potential willing to use medical contraception during the study
You will not qualify if you...
- Malignant diseases other than ovarian cancer diagnosed within 5 years, except for certain skin cancers
- Participation in other clinical trials or treatments within 4 weeks before first dose
- Prior pelvic radiotherapy, systemic chemotherapy, targeted therapy, or immune therapy for ovarian cancer
- Symptomatic or uncontrolled brain metastases or spinal cord compression
- Current use of oral or intravenous beta blockers or contraindications to propranolol
- Systemic glucocorticoids or immunosuppressive therapy within 7 days before first dose (physiological doses allowed)
- Known allogeneic organ or hematopoietic stem cell transplantation except corneal transplant
- Allergy to propranolol or its excipients
- Unrecovered toxicity or complications from prior interventions (except mild fatigue or hair loss)
- Known HIV infection
- Known hepatitis B or active hepatitis C infection
- Live vaccine within 30 days before first dose
- Pregnant or breastfeeding women
- Serious or uncontrolled systemic diseases including severe heart rhythm/conduction issues, unstable angina, heart failure NYHA class 2 or higher, recent arterial thrombosis or embolism, recent glucocorticoid-treated infectious pneumonia, active lung disease, uncontrolled infection, diverticulitis, abdominal abscess, gastrointestinal obstruction, liver cirrhosis or active hepatitis, mental disorders preventing cooperation
- Any condition or history that may interfere with study participation or outcomes as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Anhui Cancer Hospitail
Hefei, Anhui, China, 230001
Actively Recruiting
Research Team
Y
Yao Xia, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here